AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...

Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...

THOUSAND OAKS, Calif., Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha ® (evolocumab) Pushtronex ™ system (on-body infusor with prefilled cartridge), a ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused ...

The treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial [HeFH]) or mixed dyslipidemia, as an adjunct to diet: in combination with a statin or statin with ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its newer products will offset the loss of revenue from patent expirations and ...

WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease.

Repatha (evolocumab) isn’t known to interact with other medications, supplements, herbs, vitamins, vaccines, or lab tests. There are no known direct interactions between Repatha and alcohol. However, ...

Coverage from the American College of Cardiology 2017 Scientific Session. Evolocumab, the powerful cholesterol-fighting injection sold as Repatha, offers a 25% reduction in cardiovascular (CV) death, ...

THOUSAND OAKS, Calif. (Nov. 13, 2020) - Amgen (NASDAQ:AMGN) today announced a new analysis from the Repatha® (evolocumab) cardiovascular (CV) outcomes study (FOURIER) that evaluated the effectiveness ...

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...